Immune system recognition of Dermatophagoides pteronyssinus allergens (HDM allergen recognition)

Immune system recognition of Dermatophagoides pteronyssinus allergens refers to the complex series of molecular interactions between proteins derived from the European house dust mite and the human immune system. This process is initiated when allergens such as Der p 1 (a cysteine protease) and Der p 2 (a lipid-binding protein) bypass epithelial barriers and activate innate and adaptive immune pathways [1, 2]. Der p 1 facilitates its own entry by cleaving epithelial tight junction proteins, while Der p 2 acts as a functional mimic of MD-2, facilitating the activation of the Toll-like receptor 4 (TLR4) complex [3]. These interactions lead to the production of allergen-specific IgE antibodies, which sensitize mast cells and basophils, resulting in Type I hypersensitivity reactions upon re-exposure. Clinically, this recognition process is the underlying cause of house dust mite-induced asthma, allergic rhinitis, and atopic dermatitis [4]. Therapeutic interventions include allergen immunotherapy (AIT), which aims to desensitize the immune system, and biologics that target IgE or Th2-associated cytokines to mitigate the inflammatory cascade [5, 6].

Other names

House dust mite allergen recognitionDer p allergen sensitizationHDM-induced immune responseDermatophagoides pteronyssinus hypersensitivity

Allergen immunotherapy (AIT) involves the repeated administration of specific allergens to induce immunological tolerance, shifting the immune response from a Th2-mediated allergic profile to a Treg-mediated regulatory profile and increasing allergen-specific IgG4 antibodies [4, 5]. Monoclonal antibodies like omalizumab target the IgE recognition step by neutralizing free IgE, while others target downstream cytokine signaling [6].